IL255228A0 - Targeted structures of hpv16 - e7 peptide/mhc complexes and their uses - Google Patents

Targeted structures of hpv16 - e7 peptide/mhc complexes and their uses

Info

Publication number: IL255228A0
Authority: IL; Israel
Prior art keywords: hpv16; peptide; mhc complexes; targeted structures; targeted
Prior art date: 2015-05-08

Application number

IL255228A

Other languages

Hebrew (he)

Original Assignee

Eureka Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-08

Filing date

2017-10-24

Publication date

2017-12-31

2017-10-24 Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc

2017-12-31 Publication of IL255228A0 publication Critical patent/IL255228A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

IL255228A 2015-05-08 2017-10-24 Targeted structures of hpv16 - e7 peptide/mhc complexes and their uses IL255228A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562158735P	2015-05-08	2015-05-08
US201562197480P	2015-07-27	2015-07-27
PCT/US2016/031364 WO2016182957A1 (en)	2015-05-08	2016-05-06	Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof

Publications (1)

Publication Number	Publication Date
IL255228A0 true IL255228A0 (en)	2017-12-31

Family

ID=57249446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL255228A IL255228A0 (en)	2015-05-08	2017-10-24	Targeted structures of hpv16 - e7 peptide/mhc complexes and their uses

Country Status (12)

Country	Link
EP (1)	EP3294328A1 (en)
JP (1)	JP2018516879A (en)
KR (1)	KR20170141256A (en)
CN (1)	CN107847570A (en)
AU (1)	AU2016261356A1 (en)
CA (1)	CA2988397A1 (en)
IL (1)	IL255228A0 (en)
MX (1)	MX2017014056A (en)
RU (1)	RU2017142716A (en)
SG (1)	SG11201708674XA (en)
TW (1)	TW201713695A (en)
WO (1)	WO2016182957A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3365364B1 (en)	2015-10-23	2024-04-10	Eureka Therapeutics, Inc.	Antibody/t-cell receptor chimeric constructs and uses thereof
JP2020517287A (en)	2017-04-26	2020-06-18	ユーリカセラピューティックス，インコーポレイテッド	Chimeric antibody/T cell receptor constructs and uses thereof
EA202090149A1 (en) *	2017-06-28	2020-05-31	Ридженерон Фармасьютикалз, Инк.	ANTI-BINDING PROTEINS AGAINST HUMAN PAPILLOMA VIRUS (HPV) AND WAYS OF THEIR APPLICATION
EP3692063A1 (en)	2017-10-03	2020-08-12	Juno Therapeutics, Inc.	Hpv-specific binding molecules
KR102281405B1 (en) *	2017-10-20	2021-07-26	주식회사 파멥신	Anti- VISTA antibody and Use Thereof
KR102764123B1 (en) *	2018-04-05	2025-02-05	주노 쎄러퓨티크스 인코퍼레이티드	T cell receptor and engineered cells expressing it
CN110776562B (en) *	2018-07-30	2022-06-17	香雪生命科学技术（广东）有限公司	T cell receptor for identifying AFP antigen
CN113045655A (en) *	2019-12-27	2021-06-29	高诚生物医药(香港)有限公司	anti-OX 40 antibodies and uses thereof
JP7598938B2 (en)	2020-02-06	2024-12-12	アジュユニバーシティーインダストリー－アカデミックコーオペレイションファウンデーション	Fusion antibody for presenting antigen-derived T cell antigen epitope or peptide containing same on cell surface, and composition containing same
AU2021227687B2 (en)	2020-02-26	2023-02-23	Vir Biotechnology, Inc.	Antibodies against SARS-CoV-2 and methods of using the same
CN113321726B (en) *	2020-02-28	2024-05-28	香雪生命科学技术（广东）有限公司	A T cell receptor that recognizes HPV
CN113801217B (en) *	2020-06-17	2025-12-23	香雪生命科学技术（广东）有限公司	A high-affinity T-cell receptor that recognizes HPV antigens
WO2022133169A1 (en)	2020-12-18	2022-06-23	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
CN113637690A (en) *	2021-08-18	2021-11-12	武汉华美生物工程有限公司	Preparation method and application of human papilloma virus HPV16 type E7 active protein
WO2023133193A1 (en) *	2022-01-05	2023-07-13	Memorial Sloan-Kettering Cancer Center	Anti-hpv antibodies and uses thereof
WO2024050399A1 (en) *	2022-09-01	2024-03-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090304679A1 (en) *	2004-05-27	2009-12-10	Weidanz Jon A	Antibodies as T cell receptor mimics, methods of production and uses thereof

2016
- 2016-05-06 JP JP2017557069A patent/JP2018516879A/en active Pending
- 2016-05-06 MX MX2017014056A patent/MX2017014056A/en unknown
- 2016-05-06 KR KR1020177035048A patent/KR20170141256A/en not_active Withdrawn
- 2016-05-06 CA CA2988397A patent/CA2988397A1/en not_active Abandoned
- 2016-05-06 RU RU2017142716A patent/RU2017142716A/en not_active Application Discontinuation
- 2016-05-06 CN CN201680039553.5A patent/CN107847570A/en active Pending
- 2016-05-06 WO PCT/US2016/031364 patent/WO2016182957A1/en not_active Ceased
- 2016-05-06 AU AU2016261356A patent/AU2016261356A1/en not_active Abandoned
- 2016-05-06 SG SG11201708674XA patent/SG11201708674XA/en unknown
- 2016-05-06 EP EP16793285.4A patent/EP3294328A1/en not_active Withdrawn
- 2016-05-09 TW TW105114353A patent/TW201713695A/en unknown
2017
- 2017-10-24 IL IL255228A patent/IL255228A0/en unknown

Also Published As

Publication number	Publication date
JP2018516879A (en)	2018-06-28
WO2016182957A1 (en)	2016-11-17
RU2017142716A (en)	2019-06-10
MX2017014056A (en)	2018-04-10
TW201713695A (en)	2017-04-16
KR20170141256A (en)	2017-12-22
AU2016261356A1 (en)	2018-01-04
SG11201708674XA (en)	2017-11-29
CA2988397A1 (en)	2016-11-17
EP3294328A1 (en)	2018-03-21
CN107847570A (en)	2018-03-27

Publication	Publication Date	Title
IL256185A (en)	2018-02-28	Targeted constructs of ny --eso-1 peptide/mhc complexes and uses thereof
IL255228A0 (en)	2017-12-31	Targeted structures of hpv16 - e7 peptide/mhc complexes and their uses
IL293377A (en)	2022-07-01	hsd17b13 variants and their uses
PL4234581T3 (en)	2026-01-26	THERAPEUTIC ANTIBODIES AND THEIR APPLICATIONS
DK3322804T3 (en)	2021-10-04	NUKLEASE-INDEPENDENT TARGETED REDUCTION PLATFORM AND ITS APPLICATIONS
IL255949A (en)	2018-01-31	Antibodies against ox40 and their uses
EP3576765A4 (en)	2020-12-02	TARGETED MANIPULATED INTERFERON AND USES THEREOF
IL280863A (en)	2021-04-29	Ototaxin inhibitors and their uses
PL3265448T3 (en)	2022-04-25	RILUSOL PROLOCKS AND THEIR APPLICATION
PT3368534T (en)	2021-03-09	VALBENAZINE DITHOSILATE AND POLYMORPH OF THE SAME
IL252026B (en)	2021-10-31	Antibodies against complement factor c1q of human origin and uses thereof
MA40764A (en)	2017-08-01	THERAPEUTIC AGENT INDUCING CYTOTOXICITY
IL256925A (en)	2018-03-29	Targeted structures of psa peptide/mhc complexes and their uses
DK3107563T3 (en)	2021-05-25	GLYCOM TARGETED THERAPEUTIC AGENTS
MA41794A (en)	2018-01-23	MODIFIED THERAPEUTIC AGENTS AND ASSOCIATED COMPOSITIONS
MA44262A (en)	2021-03-24	BIOCONJUGATES AND USES OF THEM
LT3341027T (en)	2024-06-25	TRANSFECTION COMPLEXES AND METHODS OF THEIR USE
EP3310376A4 (en)	2019-01-23	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
DK3194564T3 (en)	2020-10-19	TRICHODERMA COMPOSITIONS AND METHODS OF APPLICATION
EP3334429C0 (en)	2024-04-24	HYPERPHENYLALANINEMIA AND TREATMENTS THEREOF
DK3102200T3 (en)	2023-05-22	Therapeutic compound and composition
DK3128005T3 (en)	2021-06-28	SIRP-ALFA VARIANT CONSTRUCTIONS AND USES THEREOF
IL256322B (en)	2022-03-01	Improved formulations of deprasirox and methods of their manufacture
EP3511407A4 (en)	2020-04-08	CHRISTENSENELLA INTESTINIHOMINIS AND ITS APPLICATION
LT3288379T (en)	2022-02-25	COMPOSITIONS AND USES OF PEPTIDES